Home » GlaxoSmithKline, Nabi to Develop Smoking Vaccine
GlaxoSmithKline, Nabi to Develop Smoking Vaccine
GlaxoSmithKline PLC and Nabi Biopharmaceuticals said they will work together to develop
vaccines to help smokers give up the habit, in a deal that could be worth more than $500 million.
The Seattle Times
The Seattle Times
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May